These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21447724)

  • 81. Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA).
    Ebbers SC; Barentsz MW; de Vries-Huizing DMV; Versleijen MWJ; Klompenhouwer EG; Tesselaar MET; Stokkel MPM; Brabander T; Hofland J; Moelker A; van Leeuwaarde RS; Smits MLJ; Braat AJAT; Lam MGEH
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1121-1132. PubMed ID: 37897617
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects.
    Wang Z; Wu J; Tian X; Hao C
    Front Med; 2019 Aug; 13(4):427-437. PubMed ID: 30798508
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
    Kratochwil C; López-Benítez R; Mier W; Haufe S; Isermann B; Kauczor HU; Choyke PL; Haberkorn U; Giesel FL
    Endocr Relat Cancer; 2011 Oct; 18(5):595-602. PubMed ID: 21791571
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki S; Strauss LG; Georgoulias V; Schuhmacher J; Haberkorn U; Karkavitsas N; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Detectability of hypervascularity in early dynamic PET depends on tracer kinetics: 18 F-FDG versus 68 Ga-DOTATOC in hepatic NET metastasis.
    Sänger P; Schierz JH; Marlowe RJ; Freesmeyer M
    Liver Int; 2014 Jan; 34(1):161. PubMed ID: 23663248
    [No Abstract]   [Full Text] [Related]  

  • 86. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Intraarterial treatment of GEP NET: (68)Ga-DOTATOC SUV cannot predict (90)Y-DOTATOC uptake.
    Brogsitter C; Faulhaber D; Kotzerke J
    Clin Cancer Res; 2011 Apr; 17(7):2065. PubMed ID: 21447724
    [No Abstract]   [Full Text] [Related]  

  • 90.
    Graham MM; Gu X; Ginader T; Breheny P; Sunderland JJ
    J Nucl Med; 2017 Sep; 58(9):1452-1458. PubMed ID: 28280220
    [No Abstract]   [Full Text] [Related]  

  • 91. Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.
    Nisa L; Savelli G; Giubbini R
    Ann Nucl Med; 2011 Feb; 25(2):75-85. PubMed ID: 21107762
    [TBL] [Abstract][Full Text] [Related]  

  • 92.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 93.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.